Targeting effector pathways in RAC1^P29S-driven malignant melanoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Malignant melanoma often harbors mutations in driver genes like BRAF and NRAS.
• Activating mutations in RAC1 are found in 4-9% of sun-exposed melanomas, impacting cell functions.
• RAC1 signaling involves key effectors: Group A p21-activated kinases (PAKs), phosphoinositol-3-kinases (PI3Ks), and serum-response factor/myocardin-related transcription factor (SRF/MRTF).

Purpose of the Study:

• To investigate the roles of PI3Ks and SRF/MRTF in RAC1-driven melanomagenesis.
• To evaluate the efficacy of inhibiting Group A PAKs, PI3Ks, and SRF/MRTF in melanoma models.

Main Methods:

• Utilized selective inhibitors: Group A PAK inhibitor (Frax-1036), pan-PI3K (BKM120), PI3Kβ inhibitors (TGX221, GSK2636771), and an SRF/MRTF inhibitor (CCG-203,971).
• Assessed the impact of these inhibitors on melanoma cell growth in vitro.
• Evaluated therapeutic effects in a zebrafish embryonic development model in vivo.

Main Results:

• Group A PAK, PI3Kβ, and pan-PI3K inhibitors effectively impeded growth of RAC1-mutant melanoma cells, but not BRAF-mutant cells.
• Selective inhibitors for PI3Kα, δ, and γ showed less efficacy.
• In vivo studies in zebrafish corroborated the in vitro findings, demonstrating therapeutic potential.

Conclusions:

• Targeting Group A PAKs, PI3Kβ, and SRF/MRTF pathways presents a promising therapeutic strategy for malignant melanoma with RAC1 mutations.
• These findings offer new insights into RAC1 signaling pathways and potential drug targets in melanoma treatment.